ABS Stock Overview
Arctic Bioscience AS, a biotechnology company, engages in developing, manufacturing, and marketing pharmaceutical and nutraceutical ingredients based on natural and cultured marine membrane lipids.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Arctic Bioscience AS Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr9.85 |
| 52 Week High | kr12.00 |
| 52 Week Low | kr7.54 |
| Beta | 0.58 |
| 1 Month Change | 3.68% |
| 3 Month Change | -6.19% |
| 1 Year Change | -3.43% |
| 3 Year Change | -58.40% |
| 5 Year Change | n/a |
| Change since IPO | -64.18% |
Recent News & Updates
Shareholder Returns
| ABS | NO Biotechs | NO Market | |
|---|---|---|---|
| 7D | -1.0% | 0.01% | 0.9% |
| 1Y | -3.4% | -66.4% | 4.6% |
Return vs Industry: ABS exceeded the Norwegian Biotechs industry which returned -67.4% over the past year.
Return vs Market: ABS underperformed the Norwegian Market which returned 4.6% over the past year.
Price Volatility
| ABS volatility | |
|---|---|
| ABS Average Weekly Movement | 7.3% |
| Biotechs Industry Average Movement | 10.1% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in NO Market | 10.5% |
| 10% least volatile stocks in NO Market | 2.9% |
Stable Share Price: ABS has not had significant price volatility in the past 3 months.
Volatility Over Time: ABS's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 17 | Christer Valderhaug | www.arctic-bioscience.com |
Arctic Bioscience AS, a biotechnology company, engages in developing, manufacturing, and marketing pharmaceutical and nutraceutical ingredients based on natural and cultured marine membrane lipids. It is developing the investigational medicinal product, HRO350 for treatment of mild-to-moderate psoriasis. The company also offers herring caviar oil and protein nutraceuticals.
Arctic Bioscience AS Fundamentals Summary
| ABS fundamental statistics | |
|---|---|
| Market cap | kr249.89m |
| Earnings (TTM) | -kr45.51m |
| Revenue (TTM) | kr33.76m |
7.4x
P/S Ratio-5.5x
P/E RatioIs ABS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ABS income statement (TTM) | |
|---|---|
| Revenue | kr33.76m |
| Cost of Revenue | kr23.98m |
| Gross Profit | kr9.78m |
| Other Expenses | kr55.29m |
| Earnings | -kr45.51m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Aug 29, 2024
| Earnings per share (EPS) | -1.79 |
| Gross Margin | 28.97% |
| Net Profit Margin | -134.84% |
| Debt/Equity Ratio | 0% |
How did ABS perform over the long term?
See historical performance and comparison